Enact Holdings, Inc.
US ˙ NasdaqGS ˙ US29249E1091

Introduction

This page provides a comprehensive analysis of the known insider trading history of James DArecca. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate James DArecca has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PBH / Prestige Consumer Healthcare Inc. Director 6,591
US:HAE / Haemonetics Corporation EVP, Chief Financial Officer 28,292
US:TXMD / TherapeuticsMD, Inc. Chief Financial Officer 123,830
US:ACT / Enact Holdings, Inc. SVP Chief Accounting Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by James DArecca. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACT / Enact Holdings, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACT / Enact Holdings, Inc. Insider Trades
Insider Sales ACT / Enact Holdings, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACT / Enact Holdings, Inc. Insider Trades
Insider Purchases HAE / Haemonetics Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HAE / Haemonetics Corporation Insider Trades
Insider Sales HAE / Haemonetics Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HAE / Haemonetics Corporation Insider Trades
Insider Purchases PBH / Prestige Consumer Healthcare Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PBH / Prestige Consumer Healthcare Inc. Insider Trades
Insider Sales PBH / Prestige Consumer Healthcare Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PBH / Prestige Consumer Healthcare Inc. Insider Trades
Insider Purchases TXMD / TherapeuticsMD, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACT / Enact Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TXMD / TherapeuticsMD, Inc. Insider Trades
Insider Sales TXMD / TherapeuticsMD, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACT / Enact Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2021-08-12 TXMD DArecca James 93,337 0.8700 1,867 43.5000 81,203 287 2.0700 -77,340 -95.24

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TXMD / TherapeuticsMD, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by James DArecca as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-06 2025-08-05 4 PBH Prestige Consumer Healthcare Inc.
Common Stock, par value $0.01 per share
A - Award 2,094 6,591 46.56
2025-06-03 2025-05-30 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -5,864 28,292 -17.17 69.38 -406,844 1,962,899
2025-06-03 2025-05-30 4 HAE HAEMONETICS CORP
Common Stock
A - Award 12,221 34,156 55.71
2025-05-20 2025-05-16 4 HAE HAEMONETICS CORP
Common Stock
A - Award 7,111 21,935 47.97
2025-05-19 2025-05-16 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -1,246 14,824 -7.75 70.31 -87,606 1,042,275
2025-05-19 2025-05-15 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -622 16,070 -3.73 69.38 -43,154 1,114,937
2025-05-05 2025-05-02 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -654 16,692 -3.77 63.85 -41,758 1,065,784
2024-08-07 2024-08-06 4 PBH Prestige Consumer Healthcare Inc.
Common Stock, par value $0.01 per share
A - Award 2,202 4,497 95.95
2024-05-21 2024-05-17 4 HAE HAEMONETICS CORP
Common Stock
A - Award 4,439 17,346 34.39
2024-05-17 2024-05-16 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -351 12,907 -2.65 94.80 -33,275 1,223,584
2024-05-17 2024-05-15 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -412 13,258 -3.01 96.49 -39,754 1,279,264
2024-05-06 2024-05-02 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -432 13,670 -3.06 93.33 -40,319 1,275,821
2023-08-03 2023-08-01 4 PBH Prestige Consumer Healthcare Inc.
Common Stock, par value $0.01 per share
A - Award 2,295 2,295
2023-05-17 2023-05-16 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -349 14,102 -2.42 89.21 -31,134 1,258,039
2023-05-17 2023-05-15 4 HAE HAEMONETICS CORP
Common Stock
A - Award 4,205 14,451 41.04
2023-05-04 2023-05-02 4 HAE HAEMONETICS CORP
Common Stock
F - Taxes -430 10,246 -4.03 81.66 -35,114 836,688
2022-05-18 2022-05-16 4 HAE HAEMONETICS CORP
Non-qualified Stock Option (Right to Buy)
A - Award 11,163 11,163
2022-05-18 2022-05-16 4 HAE HAEMONETICS CORP
Common Stock
A - Award 4,774 10,676 80.89
2022-05-04 2022-05-02 4 HAE HAEMONETICS CORP
Non-qualified Stock Option (Right to Buy)
A - Award 13,828 13,828
2022-05-04 2022-05-02 4 HAE HAEMONETICS CORP
Common Stock
A - Award 5,902 5,902
2021-08-12 2021-08-12 4 TXMD TherapeuticsMD, Inc.
Common Stock
S - Sale -93,337 123,830 -42.98 0.87 -81,203 107,732
2021-08-12 2021-08-10 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
M - Exercise -217,167 434,333 -33.33
2021-08-12 2021-08-10 4 TXMD TherapeuticsMD, Inc.
Common Stock
M - Exercise 217,167 217,167
2021-07-02 2021-07-01 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
A - Award 173,333 173,333
2021-07-02 2021-07-01 4 TXMD TherapeuticsMD, Inc.
Performance Stock Units
A - Award 346,667 346,667
2020-08-07 2020-06-18 4/A TXMD TherapeuticsMD, Inc.
Restricted Stock Units
A - Award 651,500 651,500
2020-08-07 2020-06-18 4/A TXMD TherapeuticsMD, Inc.
Performance Stock Units
A - Award 151,500 151,500
2020-06-19 2020-06-18 4 TXMD TherapeuticsMD, Inc.
Restricted Stock Units
A - Award 651,500 651,500
2020-06-19 2020-06-18 4 TXMD TherapeuticsMD, Inc.
Performance Stock Units
A - Award 151,500 151,500
2020-05-11 2020-05-08 4 AGN Allergan plc
Performance Stock Units
D - Sale to Issuer -3,534 0 -100.00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -4,957 0 -100.00
2020-05-11 2020-05-08 4 AGN Allergan plc
Stock Options
D - Sale to Issuer -1,169 0 -100.00
2020-05-11 2020-05-08 4 AGN Allergan plc
Restricted Stock Units
D - Sale to Issuer -6,324 0 -100.00
2020-05-11 2020-05-08 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
D - Sale to Issuer -3,511 0 -100.00
2020-03-10 2020-03-06 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -718 9,834 -6.80 191.95 -137,820 1,887,636
2020-03-04 2020-03-02 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 3,611 10,552 52.02 193.84 699,956 2,045,400
2020-01-02 2019-12-31 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -92 6,941 -1.31 191.17 -17,588 1,326,911
2019-03-11 2019-03-08 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -113 7,033 -1.58 145.06 -16,392 1,020,207
2019-03-11 2019-03-07 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -359 7,146 -4.78 143.00 -51,337 1,021,878
2019-03-08 2019-03-06 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 2,036 7,505 37.23 137.51 279,970 1,032,013
2019-03-06 2019-03-04 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -114 5,469 -2.04 139.12 -15,860 760,847
2019-03-06 2018-03-07 4/A AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 1,826 5,809 45.84 153.22 279,780 890,055
2019-01-03 2018-12-31 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -147 5,453 -2.62 133.66 -19,648 728,848
2018-03-09 2018-03-08 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -79 5,600 -1.39 153.50 -12,126 859,600
2018-03-08 2018-03-07 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 1,696 5,679 42.58 153.22 259,861 870,136
2018-03-08 2018-03-07 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -93 3,983 -2.28 153.22 -14,249 610,275
2018-03-06 2018-03-05 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -70 4,076 -1.69 148.73 -10,411 606,223
2018-03-06 2018-03-02 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -76 4,146 -1.80 144.02 -10,946 597,107
2018-01-02 2017-12-29 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -100 4,222 -2.31 163.58 -16,358 690,635
2017-10-30 2017-10-26 4 AGN Allergan plc
Performance Based Restricted Share Unit
M - Exercise -799 0 -100.00
2017-10-30 2017-10-26 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
M - Exercise 799 4,322 22.68
2017-03-09 2017-03-08 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -77 3,523 -2.14 239.44 -18,437 843,547
2017-03-09 2017-03-07 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 1,085 3,600 43.14 239.60 259,966 862,560
2017-03-07 2017-03-05 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -66 2,515 -2.56 245.63 -16,212 617,759
2017-03-07 2017-03-04 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -72 2,581 -2.71 245.63 -17,685 633,971
2017-02-03 2017-02-01 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
C - Conversion -238 0 -100.00
2017-02-03 2017-02-01 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
F - Taxes -92 2,653 -3.35 229.32 -21,097 608,386
2017-02-03 2017-02-01 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 238 2,745 9.49 229.32 54,578 629,483
2016-05-12 2016-03-08 4 AGN Allergan plc
Ordinary Shares, par value $0.0001
A - Award 914 2,507 57.38 284.43 259,969 713,066
2015-03-09 2015-03-05 4 ACT Actavis plc
Ordinary Shares, par value ($0.0001)
F - Taxes -45 1,593 -2.75 295.70 -13,306 471,050
2015-03-09 2015-03-05 4 ACT Actavis plc
Ordinary Shares, par value ($0.0001)
A - Award 456 1,638 38.58
2015-03-09 2015-03-05 4 ACT Actavis plc
Ordinary Shares, par value ($0.0001)
F - Taxes -33 1,182 -2.72 295.70 -9,758 349,517
2015-03-06 2015-03-04 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 1,169 1,169
2015-03-06 2015-03-04 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
A - Award 877 1,215 259.47 296.14 259,715 359,810
2014-07-03 2014-07-01 4 ACT Actavis plc
Stock Option (Right to Buy)
A - Award 4,957 4,957
2014-07-03 2014-07-01 4 ACT Actavis plc
Performance-Based Restricted Stock Unit
A - Award 1,816 1,816
2014-05-13 2014-05-09 4 ACT Actavis plc
Ordinary Shares, par value $0.0001
A - Award 338 338 197.05 66,603 66,603
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)